Plasma fractionation market seen nearly doubling by 2035

Market Research Future projects the global plasma fractionation market will grow from $45.1 billion in 2026 to $98.8 billion by 2035. Demand is being driven by rising immunodeficiency and autoimmune disease cases, more plasma collection capacity, and government pushes for domestic supply security.

Why it matters: - Plasma-derived therapies are becoming more central to treatment for immunodeficiency, autoimmune disease and critical care. - The market is expected to expand from $45.1 billion in 2026 to $98.8 billion by 2035, signaling strong demand for immunoglobulins, albumin and related products. - Governments are treating plasma supply as a health-security issue, not just a purchasing decision.

What happened: - Market Research Future said the global plasma fractionation market will rise from $45.1 billion in 2026 to $98.8 billion by 2035. - The forecast implies a 9.1% compound annual growth rate from 2026 to 2035. - The market base was estimated at $41.4 billion in 2025. - The report was published Aug. 12, 2026. - A free sample is available here.

The details: - Immunoglobulins held about 45% of revenue in 2025 and remained the dominant product type. - Albumin was the second-largest product segment and is projected to grow at 8.6% annually through 2035. - Neurology accounted for about 30% of revenue in 2025, led by use in CIDP, Guillain-Barré syndrome and myasthenia gravis. - Immunology is the fastest-growing application segment at a 9.8% CAGR through 2035. - Hospitals and clinics held about 62% of end-user share in 2025. - Specialty infusion centers are the fastest-growing end-user segment at 11.5% CAGR through 2035. - Centrifugation remains the dominant technology for plasma collection and initial separation. - Chromatography is the fastest-growing technology segment. - Several large-scale facilities in the U.S. and Europe commissioned between 2023 and 2025 adopted continuous-flow chromatography systems, cutting batch processing time by up to 30%. - North America led the market with about 38% share in 2025. - The U.S. accounted for roughly 82% of North American revenue. - Europe was the second-largest regional market at $11.6 billion in 2025. - Asia-Pacific was the fastest-growing region at 11.2% CAGR through 2035. - China held about 48% of Asia-Pacific revenue. - The Middle East and Africa is projected to grow at 9.8% CAGR through 2035. - South America reached $2.5 billion in 2025, with Brazil contributing about 58% of regional revenue.

Between the lines: - The report points to a shift from reactive hospital spending toward preventive therapy, especially for immunoglobulin use. - Domestic fractionation capacity is gaining importance as countries try to reduce import dependence and improve resilience. - China, India, Brazil and parts of Europe are pushing local production through subsidies, mandates and faster approvals. - The competitive landscape remains concentrated, with the top five companies holding an estimated 55% to 65% of global revenue. - CSL Behring, Grifols and Takeda remain the largest global players by revenue share. - The report also highlights growing investment in precision plasma tools, with more than $800 million raised since 2023 for biologics decision-support startups.

What's next: - The report expects continuous chromatography and membrane-based fractionation to keep expanding as companies add capacity. - By 2030, it forecasts that about 40% of newly diagnosed primary immunodeficiency patients will undergo genetic screening followed by matched immunoglobulin therapy protocols. - The market outlook suggests more spending will flow to domestic collection networks, outpatient infusion and diagnostic-linked treatment pathways. - Read the detailed report